A decade after the Human Genome Project's completion, scientists have an improved understanding of nearly 5,000 diseases but personalized treatments for a relative handful. Ten years ago, four FDA-approved labels included information on genetics, and now the figure exceeds 100. Genes operate in networks, making development of targeted therapies elusive, says Eric Schadt, chairman of genetics and genomic sciences at Mount Sinai Icahn School of Medicine. "We keep learning how much we really don't know and how much further we need to go," Schadt said.
Precision medicine still developing 10 years after genome is mapped
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|